抗生素联合治疗小儿社区获得性肺炎的临床疗效及安全性

Clinical efficacy and safety of antibiotic combination therapy in the treatment of community-acquired pneumonia in children.

作者信息

Yang Huan, Xiang Zhengke, Chen Peiwei

机构信息

Huan Yang, Department of Pediatrics, The Central Hospital of Enshi, Tujia and Miao Autonomous Prefecture, Enshi, Hubei, 445000, China.

Zhengke Xiang, Department of Pediatrics, The Central Hospital of Enshi, Tujia and Miao Autonomous Prefecture, Enshi, Hubei, 445000, China.

出版信息

Pak J Med Sci. 2025 Apr;41(4):958-962. doi: 10.12669/pjms.41.4.10236.

DOI:10.12669/pjms.41.4.10236

PMID:40290216

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12022586/

Abstract

OBJECTIVE

To determine the efficacy and safety of cefotaxime combined with azithromycin in the treatment of children with community-acquired pneumonia (CAP) and its effect on inflammatory factors.

METHODS

This is an observational study. A total of 118 children with CAP admitted to our hospital from June, 2022 to December, 2023 were randomly selected. According to the random number table method, they were divided into a control group and a combination treatment group, with 59 children in each group. The children in the control group were treated with azithromycin, and those in the combination treatment group were treated with cefotaxime combined with azithromycin. Both groups were treated for a week. The disappearance time of symptoms (fever, pulmonary rales, cough) and the improvement of inflammatory indicators (serum interleukin-6 (IL-6), serum C-reactive protein (CRP), and serum interleukin-8 (IL-8)) after treatment were compared. The clinical efficacy and adverse reactions were compared between the two groups.

RESULTS

The disappearance time of fever, pulmonary rales, and cough in the combination treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum levels of CRP, IL-6, and IL-8 in the two groups were lower than those before treatment, and the reduction in the combination treatment group was larger than that in the control group (P < 0.05). The total efficacy of the combination treatment group was significantly higher than that of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05).

CONCLUSION

Cefotaxime combined with azithromycin in the treatment of CAP in children can significantly improve the efficacy, quickly relieve clinical symptoms, improve the body's defense mechanism, inhibit inflammatory response, and has high safety, which is worthy of clinical promotion.

摘要

目的

探讨头孢噻肟联合阿奇霉素治疗儿童社区获得性肺炎（CAP）的疗效、安全性及其对炎症因子的影响。

方法

本研究为观察性研究。选取2022年6月至2023年12月我院收治的118例CAP患儿，采用随机数字表法分为对照组和联合治疗组，每组59例。对照组患儿给予阿奇霉素治疗，联合治疗组患儿给予头孢噻肟联合阿奇霉素治疗。两组均治疗1周。比较两组治疗后症状（发热、肺部啰音、咳嗽）消失时间及炎症指标（血清白细胞介素-6（IL-6）、血清C反应蛋白（CRP）、血清白细胞介素-8（IL-8））改善情况。比较两组临床疗效及不良反应。